Skip to main content

The Cigna Group(CI-N)

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

2 Underappreciated Dividend Stocks to Buy in September and Hold Forever

Motley Fool - Sun Sep 3, 5:47AM CDT

Now's a great time to be a value-conscious investor. There's a sale on some underappreciated dividend stocks that have been beaten down in recent weeks.

Over the past year, these three healthcare businesses combined generated more than $22 billion in free cash flow. Moreover, they're not at all shy about sharing their profits with investors in the form of share buybacks and rapidly rising dividend payouts.

Couple looking for stocks on their tablet.

Image source: Getty Images.

Here's how they could make excellent, long-term additions to just about any income-seeking investor's portfolio.

CVS Health

CVS Health(NYSE: CVS) is famous for its retail pharmacies, but it's actually a vertically integrated healthcare conglomerate that leverages its retail footprint to fuel the growth of related businesses.

The stock's been beaten down about 22% in 2023, partly because one of its most successful vertical integrations, its pharmacy benefits management (PBM) business, could be in trouble. At recent prices, the stock offers a juicy 3.7% dividend yield.

Health plan sponsors hire PBMs to decide which prescription drugs plan members can access without incurring additional costs. With 110 million members at the end of June, CVS Health's PBM is the country's largest, which allows it to negotiate for huge rebates from drugmakers that want preferred positioning on its formulary. Unfortunately for CVS Health's investors, plan sponsors seem fed up with PBMs that don't share as much of those rebates as they would like.

Last year, Centene ended its contract with CVS Health in favor of Cigna's PBM. In August, Blue Shield of California brought in Mark Cuban's Cost Plus Drugs, Amazon, and others to jointly handle most of its members' pharmacy benefits while relegating CVS Health to just specialty pharma services.

More companies following in Blue Shield's lead could spell trouble in the short term. However, the market appears to be undervaluing the long-run potential for Aetna, CVS Health's benefits management business. Recent acquisitions of Signify Health and Oak Tree Health make it a leading employer of American healthcare practitioners. An ability to send an increasing number of patients to service providers it employs directly is a big advantage that should keep profits rolling in.


If you'd like to invest in a more straightforward business than CVS Health, consider Medtronic(NYSE: MDT). It's the largest company in the world that's focused on developing and manufacturing medical devices.

Medtronic shares have fallen around 7.1% over the past month despite an encouraging fiscal first-quarter earnings report. At its beaten-down price, the stock offers a 3.4% dividend yield, and its dividend-raising track record is hard to beat. It's raised its payout every year since 1977 at an average rate of 16% annually.

Medtronic recently impressed Wall Street analysts with a strong start to its fiscal 2024, which ends next January. Many of the devices Medtronic sells, such as spinal cord stimulators for chronic pain or leadless pacemakers for abnormal heartbeats, require lots of doctor visits that eventually culminate in a surgical procedure.

COVID-19 left a lasting impression on Medtronic that is finally lifting. During the fiscal fourth quarter that ended on July 28, recovering procedure volume pushed total sales 6% higher year over year.

Returning to business as usual allowed adjusted earnings to rise 6% year over year to $1.20 per share in the fiscal first quarter. This is a lot more than the company needs to cover its dividend payout, which is currently set at just $0.69 per share.

The company generated $4.4 billion in free cash flow over the past 12 months and a long-awaited return to business as usual will help push profits higher. With a commitment to returning at least half of free cash flow to shareholders, buying the stock now to hold for the long run makes a lot of sense.

10 stocks we like better than CVS Health
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and CVS Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of August 28, 2023

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Cory Renauer has positions in and CVS Health. The Motley Fool has positions in and recommends The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.

Paid Post: Content produced by Motley Fool. The Globe and Mail was not involved, and material was not reviewed prior to publication.